Literature DB >> 12824861

Development of acromegaly in patients with prolactinomas.

Marianne Andersen1, Casper Hagen, Jan Frystyk, Henrik Daa Schroeder, Claus Hagen.   

Abstract

OBJECTIVES: Patients with prolactinomas and patients with acromegaly often have heterogenous adenomas. In this study we have focused on patients with prolactinomas who developed acromegaly and acromegalic patients with hyperprolactinaemia. Our hypothesis is that some patients with hyperprolactinaemia may develop clinical acromegaly.
METHODS: We have included patients examined at department M, Odense University Hospital between 1996 and 2001. Seventy-eight patients with prolactinomas, 65 females and 13 males, with a median age (range) of 30 Years (14-74) and 47 Years (20-66), respectively, were included in the study.
RESULTS: In females and males the median prolactin (PRL) levels were 90 microg/l (27-4700; normal values (NV) <or=23) and 1075 microg/l (24-6500; NV <or=14), respectively. The PRL levels were significantly higher in males compared with females (P<0.002). Fifty-nine patients with acromegaly, 24 females and 35 males, with a median age (range) of 45 Years (24-70) and 53 Years (19-70), respectively, were included. Seven of the 24 females had hyperprolactinaemia, with PRL levels of 90 microg/l (27-494). Thirteen of the 35 males had hyperprolactinaemia with PRL levels of 47 microg/l (17-251). Three females with prolactinomas developed acromegaly clinically and biochemically. These patients had a normal low GH level and/or a normal IGF-I level at first diagnosis.
CONCLUSIONS: Our findings suggest that there is a common group of patients with a pituitary adenoma who secrete PRL and GH unsynchronously. Some of these patients have clinical acromegaly at diagnosis and some patients diagnosed as prolactinomas will develop acromegaly. We suggest an annual IGF-I measurement as a screening test.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824861     DOI: 10.1530/eje.0.1490017

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

Review 1.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

2.  Effects of cabergoline therapy on serum IGF-1 concentrations in prolactinoma patients.

Authors:  Pedro Iglesias; Carles Villabona; Juan J Díez
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

3.  Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.

Authors:  Lukas Andereggen; Janine Frey; Emanuel Christ
Journal:  Endocrine       Date:  2020-12-04       Impact factor: 3.633

4.  IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.

Authors:  Amit Akirov; Yona Greenman; Benjamin Glaser; Irena S'chigol; Yossi Mansiterski; Yoav Eizenberg; Ilana Shraga-Slutzky; Ilan Shimon
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

Review 5.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

6.  Somatotropin adenoma and resistance to thyroid hormone.

Authors:  D Berker; Y Aydin; Y A Tutuncu; S Isik; T Delibasi; M Berker; S Guler; N Kamel
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

7.  Late presentation of acromegaly in medically controlled prolactinoma patients.

Authors:  Ekaterina Manuylova; Laura M Calvi; Catherine Hastings; G Edward Vates; Mahlon D Johnson; William T Cave; Ismat Shafiq
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-10-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.